Last $140.00 USD
Change Today 0.00 / 0.00%
Volume 0.0
SVYSF On Other Exchanges
Symbol
Exchange
EN Brussels
OTC US
OTC US
Frankfurt
As of 8:10 PM 11/12/14 All times are local (Market data is delayed by at least 15 minutes).

solvay sa (SVYSF) Snapshot

Open
$140.00
Previous Close
$140.00
Day High
$140.00
Day Low
$140.00
52 Week High
07/21/14 - $170.10
52 Week Low
10/16/14 - $134.77
Market Cap
11.9B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
84.7M
EX-Date
01/20/15
P/E TM
--
Dividend
$3.42
Dividend Yield
3.12%
Current Stock Chart for SOLVAY SA (SVYSF)

Related News

No related news articles were found.

solvay sa (SVYSF) Related Businessweek News

No Related Businessweek News Found

solvay sa (SVYSF) Details

Solvay SA is engaged in the chemical and plastic businesses worldwide. It operates in five segments: Advanced Formulations, Advanced Materials, Performance Chemicals, Functional Polymers, and Corporate & Business Services. The company offers chemical products, including advanced materials, barium strontium, calcium chloride, caustic soda, chlorinated products, fluor, peroxygen products, polyglycerols, precipitated calcium carbonate, soda ash, and sodium bicarbonate. It also provides specialty polymers, such as Spire ultra polymers, Solviva biomaterials, sulfone polymers, high-performance polyamides, liquid crystal polymers, high-barrier polymers, specialties, fluorinated fluids, fluoroelastomers/perfluoroelastomers, partially-fluorinated polymers, fluoropolymer coatings, fully-fluorinate polymers, polymer processing aids, and cross-linkable compounds; and vinyls comprising Benvic plasticized PVC compounds, Benvic PVC alloys, Benvic rigid PVC compounds, Nidacell, SolVin copolymers, SolVin general purpose, SolVin specialties, and Vinyloop regenerated PVC. In addition, the company offers additives, diphenols and derivatives, engineering plastics, fluorinated compounds, intermediates, phosphorus derivatives, polyamide fibers, precipitated silica, rare earths, mixed oxides, aluminas, solvents, specialty polymers and monomers, sulfuric acid, surfactants, textile yarns, staple fiber, and industrial yarns. Further, it provides energy services comprising energy optimization and carbon dioxide emissions reduction services; and eco services, such as acetate tow and sulfuric acid regeneration services. The company’s products are used in consumer goods and healthcare; automotive and aeronautics; building and construction; electrical and electronics; agro, feed, and food; energy and environment; and industrial applications. Solvay SA was founded in 1863 and is based in Brussels, Belgium.

29,400 Employees
Last Reported Date: 11/13/14
Founded in 1863

solvay sa (SVYSF) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: €2.1M
Compensation as of Fiscal Year 2013.

solvay sa (SVYSF) Key Developments

Solvay SA, Q3 2014 Earnings Call, Nov 13, 2014

Solvay SA, Q3 2014 Earnings Call, Nov 13, 2014

Solvay SA Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Reiterates Earnings Guidance for the Year 2014

Solvay SA reported consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's sales were EUR 2,688 million compared to EUR 2,485 million a year ago. Net sales were EUR 2,585 million compared to EUR 2,395 million a year ago. REBIT was EUR 257 million compared to EUR 229 million a year ago. EBIT was EUR 226 million compared to EUR 195 million a year ago. Result before taxes was EUR 158 million compared to EUR 136 million a year ago. Result from continuing operations was EUR 100 million compared to EUR 83 million a year ago. Net income was EUR 123 million compared to EUR 103 million a year ago. Net income Solvay share was EUR 115 million compared to EUR 92 million a year ago. Diluted EPS from continuing operations was EUR 1.12 compared to EUR 0.82 a year ago. Diluted EPS was EUR 1.37 compared to EUR 1.09 a year ago. REBITDA was EUR 458 million compared to EUR 418 million a year ago. Adjusted REBITDA was EUR 458 million compared to EUR 418 million a year ago. Adjusted sales were EUR 2,688 million compared to EUR 2,485 million a year ago. Adjusted net sales were EUR 2,585 million compared to EUR 2,395 million a year ago. Adjusted REBIT was EUR 284 million compared to EUR 264 million a year ago. Adjusted EBIT was EUR 254 million compared to EUR 231 million a year ago. Adjusted result before taxes was EUR 186 million compared to EUR 171 million a year ago. Adjusted result from continuing operations was EUR 118 million compared to EUR 109 million a year ago. Adjusted net income was EUR 141 million compared to EUR 129 million a year ago. Adjusted net income Solvay share was EUR 133 million compared to EUR 118 million a year ago. Adjusted diluted EPS from continuing operations was EUR 1.34 compared to EUR 1.12 a year ago. Adjusted diluted EPS was EUR 1.58 compared to EUR 1.41 a year ago. Cash flow from operating activities was EUR 362 million compared to EUR 420 million a year ago. Acquisition of tangible & intangible assets was EUR 239 million compared to EUR 183 million a year ago. For the nine months, the company's sales were EUR 7,935 million compared to EUR 7,660 million a year ago. Net sales were EUR 7,639 million compared to EUR 7,352 million a year ago. REBIT was EUR 797 million compared to EUR 669 million a year ago. EBIT was EUR 691 million compared to EUR 498 million a year ago. Result before taxes was EUR 451 million compared to EUR 304 million a year ago. Result from continuing operations was EUR 302 million compared to EUR 206 million a year ago. Net loss was EUR 127 million compared to net income of EUR 304 million a year ago. Net loss Solvay share was EUR 110 million compared to net income of EUR 264 million a year ago. Diluted EPS from continuing operations was EUR 3.26 compared to EUR 1.94 a year ago. Diluted LPS was EUR 1.31 compared to diluted EPS of EUR 3.14 a year ago. Adjusted sales were EUR 7,935 million compared to EUR 7,660 million a year ago. Adjusted net sales were EUR 7,639 million compared to EUR 7,352 million a year ago. Adjusted REBIT was EUR 879 million compared to EUR 784 million a year ago. Adjusted EBIT was EUR 773 million compared to EUR 614 million a year ago. Adjusted result before taxes was EUR 533 million compared to EUR 420 million a year ago. Adjusted result from continuing operations was EUR 358 million compared to EUR 292 million a year ago. Adjusted net loss was EUR 69 million compared to net income of EUR 393 million a year ago. Adjusted net loss Solvay share was EUR 53 million compared to net income of EUR 352 million a year ago. Adjusted diluted EPS from continuing operations was EUR 3.93 compared to EUR 2.96 a year ago. Adjusted diluted LPS was EUR 0.63 compared to diluted EPS of EUR 4.19 a year ago. Cash flow from operating activities was EUR 753 million compared to EUR 777 million a year ago. Acquisition of tangible & intangible assets was EUR 632 million compared to EUR 516 million a year ago. REBITDA was EUR 1,369 million compared to EUR 1,237 million a year ago. The company reiterates its confidence for 2014 and confirms that it expects high single-digit REBITDA growth. While vigilant about the uncertain and challenging macro-economic and geopolitical context, the Group is well-positioned to grow its earnings in this last quarter compared to last year and is determined to generate a strong free cash flow.

Solvay To Look For Alternatives To Sell Solvay Indupa

Solvay SA (ENXTBR:SOLB) will, as soon as possible, examine alternative options to sell Solvay Indupa S.A.I.C. (BASE:INDU). This is because Braskem's planned acquisition of a 70.59% stake in Solvay Indupa was rejected due to potential anti-competitive concerns.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SVYSF:US $140.00 USD 0.00

SVYSF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eastman Chemical Co $75.61 USD +0.83
Kerry Group PLC €57.55 EUR -0.25
Koninklijke DSM NV €50.27 EUR +0.23
Merck KGaA €78.43 EUR +0.316
Novozymes A/S kr263.60 DKK +2.30
View Industry Companies
 

Industry Analysis

SVYSF

Industry Average

Valuation SVYSF Industry Range
Price/Earnings 24.6x
Price/Sales 0.8x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOLVAY SA, please visit www.solvay.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.